SCHEMBL1284898

SCHEMBL1284898

[CH2]c1cccc2sc(NC(=O)OC(C)(C)C)nc12

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.55
LCK P06239 12/20 0.50
DYRK1A Q13627 2/20 0.48
DUSP3 P51452 1/20 0.43
CHRM4 P08173 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23183609 0.86 DYRK1A (0.67) MAPTLCKDYRK1ADUSP3CHRM4
SCHEMBL1284899 0.86 MAPT (0.76) MAPTLCK
SCHEMBL3283781 0.85 MAPT (0.55) MAPTLCKDYRK1ADUSP3
SCHEMBL23974266 0.85 LCK (0.56) MAPTLCKDYRK1A
SCHEMBL29454481 0.85 LCK (0.56) MAPTLCKDYRK1A
SCHEMBL3053547 0.84 DYRK1A (0.70) MAPTLCKDYRK1ADUSP3CHRM4
SCHEMBL21839507 0.84 MAPT (0.54) MAPTLCKDYRK1A
SCHEMBL16743933 0.84 MEN1 (0.62) MAPTLCKDYRK1A
SCHEMBL3212819 0.84 MAPT (0.54) MAPTLCKDYRK1A
SCHEMBL31733133 0.82 MAPT (0.53) MAPTLCKDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427451-B1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CO LTD (JP) 2019-03-20 EP disclosed
US-20180305373-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism BioLab Co., Ltd. (JP) 2018-10-25 US disclosed
US-10017522-B2 Alpha helix mimetics and methods relating thereto Prism BioLab Co., Ltd. (JP) 2018-07-10 US disclosed
US-20150368262-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism BioLab Co., Ltd. (JP) 2015-12-24 US disclosed
US-9040531-B2 Alpha helix mimetics and methods relating thereto Prism BioLab Co., Ltd. (JP) 2015-05-26 US disclosed
US-20120088770-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368262-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO MAPT 1638/4885LCK 4216/4885DYRK1A 4869/4885
US-20120088770-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO MAPT 1638/4885LCK 4216/4885DYRK1A 4869/4885
US-20180305373-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO MAPT 1638/4885LCK 4216/4885DYRK1A 4869/4885
US-10017522-B2 Alpha helix mimetics and methods relating thereto PLOD3, COL1A1, THPO MAPT 1638/4885LCK 4216/4885DYRK1A 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.